Gsa Capital Partners LLP Allovir, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
Shares
10 transactions
Others Institutions Holding ALVR
# of Institutions
49Shares Held
21.1MCall Options Held
41KPut Options Held
100-
Siren, L.L.C. New York, NY6.6MShares$63.1 Million0.12% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.03MShares$29 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$25.3 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA1.91MShares$18.3 Million0.06% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ664KShares$6.36 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $891M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...